- India sales for Sun Pharma reached 41.45 billion rupees, surpassing the estimate of 39.43 billion rupees.
- US revenue was $466 million, which was below the estimate of $506.3 million.
- Revenue from Emerging Markets was $284 million, higher than the expected $279.5 million.
- Sales from the rest of the world totaled $190 million, which fell short of the estimate of $205 million.
- Sales of active pharmaceutical ingredients stood at 4.95 billion rupees.
- Research and Development (R&D) expenses amounted to 7.94 billion rupees.
- EBITDA was 36.08 billion rupees, exceeding the estimate of 34.05 billion rupees.
- EBITDA margin was recorded at 28.5%.
- There are currently 27 buy ratings, 10 hold ratings, and 3 sell ratings for Sun Pharma.
Sun Pharmaceutical Industries on Smartkarma
Analyst coverage of Sun Pharmaceutical Industries on Smartkarma by Joe Jasper indicates a cautious sentiment with a bull lean. In the research report titled “Pullback Underway; Getting Defensive; Long-Term RS Bottoms for Defensives Is a Reason for Caution,” Jasper highlights the ongoing pullback in the market and advises caution. While maintaining a long-term bullish outlook, the report mentions potential supports to monitor at $110 on MSCI ACWI and $41-42 on MSCI EM to assess the depth of the pullback. Jasper points out concerning trends such as the S&P 500 violating its 20-day moving average and Europe’s EURO STOXX 50 showing weakness.
A look at Sun Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Sun Pharmaceutical Industries is positioned well for long-term growth. With strong scores in Dividend, Growth, and Resilience, the company shows promise for investors looking at consistent returns and stability. Its focus on manufacturing and marketing pharmaceuticals for both domestic and international markets, particularly in key areas such as diabetes, cardiology, and neurology, provides a solid foundation for future expansion and success.
Additionally, Sun Pharmaceutical Industries‘ high score in Resilience indicates its ability to weather market fluctuations and challenges, adding a layer of security for potential investors. While the scores for Value and Momentum are moderate, the company’s overall outlook remains positive, making it an attractive option for those seeking a balanced investment opportunity in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
